Kallikrein gene therapy: a new strategy for hypertensive diseases

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Molecular Medicine

Background:

• The tissue kallikrein-kinin system is implicated in blood pressure regulation and hypertension.
• Hypertension remains a significant global health challenge requiring novel therapeutic strategies.

Purpose of the Study:

• To investigate the efficacy of somatic gene delivery of human tissue kallikrein for treating hypertension.
• To evaluate different gene delivery methods and routes in a rat model of genetic hypertension.

Main Methods:

• Human tissue kallikrein gene constructs were designed and incorporated into adenoviral vectors.
• Gene delivery was performed in spontaneously hypertensive rats (SHR) via various routes (intramuscular, intravenous, portal vein, intraperitoneal, intracerebroventricular).
• Human tissue kallikrein expression and its effect on blood pressure were assessed using ELISA and physiological measurements.

Main Results:

• A single administration of naked human kallikrein DNA constructs led to an 8-week sustained reduction in blood pressure.
• Adenoviral-mediated gene delivery demonstrated high efficiency of human tissue kallikrein expression.
• Recombinant kallikrein was primarily produced in the liver and secreted into circulation, as indicated by reporter gene studies.

Conclusions:

• Somatic gene delivery of human tissue kallikrein effectively reduces blood pressure in genetically hypertensive rats.
• This study provides crucial data supporting gene therapy as a potential treatment for human hypertension.
• The findings highlight the therapeutic potential of targeting the kallikrein-kinin system for cardiovascular disease management.